Royal Philips a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global healthcare survey of its kind. The report draws insights on key concerns from healthcare professionals and patients in 16 countries, including Australia, Indonesia, and South Korea.

皇家飞利浦是健康技术领域的全球领导者，今天发布了其第10届年度未来健康指数（FHI）报告的亚太地区（APAC）调查结果，这是同类型中规模最大的全球医疗保健调查。该报告从包括澳大利亚、印度尼西亚和韩国在内的16个国家的医疗保健专业人士和患者中得出了关键问题的见解。

Findings show that despite strong optimism about artificial intelligence’s (AI) potential to ease pressure on APAC’s healthcare systems, trust and implementation concerns persist..

研究结果显示，尽管人们普遍对人工智能（AI）缓解亚太地区医疗系统压力的潜力持乐观态度，但信任和实施方面的担忧依然存在。

“The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data,” said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC.

“对人工智能的需求从未如此迫切。我们的调查显示，患者焦急地等待了一个多月才得到专科护理，而一些医疗专业人员由于患者数据不完整，每年损失大约四周的临床工作时间，”飞利浦日本高级副总裁兼代表董事、飞利浦亚太区代理总经理贾斯珀·韦斯特林克表示。

“There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people.”.

“在我们努力为更多人提供更好医疗服务的过程中，人工智能显然能够帮助临床医生更快地采取行动、做出更好的决策，并更早地预测患者的需求。”

Worsening patient outcomes because of care delays call for accelerated AI

因护理延误导致患者预后恶化，需要加速推进人工智能。

About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days.

调查显示，亚太地区约三分之二的患者（66%）需要等待将近一个半月才能见到专科医生，平均等待时间为47天。

Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times.

一般来说，亚太地区三分之一的患者 (33%) 表示他们的健康因延迟看医生而恶化，其中四分之一 (25%) 的患者最终因漫长的等待时间而住院。

AI has the potential to transform care delivery and significantly improve patient outcomes across APAC.

人工智能有潜力变革亚太地区的医疗服务提供方式，并显著改善患者预后。

Workforce challenge and data burdens call for AI relief

劳动力挑战和数据负担需要人工智能的帮助来缓解。

Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to    _ incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago..

亚太地区四分之三的医疗保健专业人员 (76%) 报告称，由于患者数据不完整或无法访问，他们损失了宝贵的临床时间，其中近三分之一 (31%) 的人员每个班次损失超过 45 分钟，相当于每位专业人员每年损失 23 天的时间。同样，五分之二 (39%) 的临床医生表示，与五年前相比，他们现在陪伴病人的时间减少了，而花在行政任务上的时间增多了。

These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden.1 About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented:.

这些加剧了亚太地区医疗专业人员所面临的工作力挑战，正如世界卫生组织估计的那样。仅东南亚地区到2030年的卫生工作者短缺人数将达到690万，占全球短缺负担的近40%。约300名接受调查的医疗专业人员分享了以下担忧，如果不实施人工智能：。

Addressing AI concerns from HCPs and patients crucial for widespread adoption

解决医疗保健提供者和患者对人工智能的担忧对于广泛采用至关重要

A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes..

亚太地区81%的医疗保健专业人员参与其所在机构的新技术研发。然而，39%的人认为所开发的新技术并未满足他们的需求。关于责任的担忧依然存在，71%的人对使用人工智能的法律责任表示担忧，而66%的人担心人工智能应用中的潜在数据偏见可能扩大健康结果的差异。

Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%)..

在患者中，大多数 (75%) 人欢迎增加技术的使用，只要这能改善他们获得医疗服务的机会并使他们受益。大约一半的人担心这可能会减少与医生面对面的时间 (51%)，并且在医疗保健中引入新技术时担心数据安全 (54%)。

Trust key to transforming healthcare in APAC

信任是推动亚太地区医疗保健转型的关键

For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area..

大多数受访的医疗保健专业人员（84%）认为，建立对人工智能的信任需要涉及对指南、问题和责任的支持。此外，医疗保健专业人员提到开发基于证据、透明且受监控的人工智能解决方案（72%），其次是关于数据安全问题的保证，有51%的医疗保健专业人员在这一领域寻求明确性。

For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%).

对于患者而言，约四分之三（74%）的人欢迎在医疗保健中使用更多技术，只要这有助于更容易见到医疗专业人员，并且有助于改善像他们这样的患者的护理（75%）。

Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies.

医护人员在建立患者与人工智能之间的信任方面起着关键作用。大多数患者（86%）表示，如果从医生那里听到关于医疗领域中使用人工智能的信息，他们会感到更加放心，这表明医生是有关此类技术的可信信息来源。

“It’s essential to foster trust of AI-powered technologies among healthcare professionals and patients,” said Jasper. “This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI’s full potential, enabling responsible, inclusive integration across APAC’s healthcare systems.”.

“培养医疗专业人员和患者对人工智能技术的信任至关重要，”贾斯珀表示。“这将推动其广泛采用和有效实施。全行业的合作将有助于我们解决信任缺口，充分释放人工智能的潜力，实现其在亚太地区医疗系统中的负责任且包容的整合。”

For details on the Future Health Index methodology and to access the full Future Health Index

有关未来健康指数方法的详细信息并获取完整的未来健康指数，请访问

For further information, please contact:

如需更多信息，请联系：

Jane Yeo

简·叶

Head of Communications and Brand, Philips APAC E-mail: jane.yeo@philips.com

亚太地区飞利浦通讯与品牌主管电子邮件：jane.yeo@philips.com

FleishmanHillard on behalf of Philips

飞利浦委托福莱国际传播咨询公司

E-mail: philips.corporate@omnicomprgroup.com

电子邮件：philips.corporate@omnicomprgroup.com

About the Future Health Index 2025

关于未来健康指数2025

The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people.

未来健康指数是全球最大规模的同类调查，分析了多国医疗专业人士和患者的优先事项与视角。《未来健康指数2025》探讨创新技术，尤其是人工智能，如何赋能医疗专业人士为更多人提供更好的医疗服务。

For more information, or to download the full FHI 2025 Global Report, visit www.philips.com/futurehealthindex-2025..

欲了解更多信息或下载完整的FHI 2025全球报告，请访问 www.philips.com/futurehealthindex-2025。

About Royal Philips

关于皇家飞利浦

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on

皇家飞利浦（纽约证券交易所代码：PHG，阿姆斯特丹证券交易所代码：PHIA）是一家领先的健康技术公司，专注于

improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home..

通过有意义的创新改善人们的健康和福祉。飞利浦以患者和人民为中心的创新利用先进技术，并结合深入的临床和消费者洞察，为消费者提供个人健康解决方案，为医疗机构及其患者提供专业的健康解决方案，覆盖医院和家庭场景。

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health.

总部位于荷兰的飞利浦是诊断影像、超声、图像引导治疗、患者监护和企业信息学以及个人健康领域的领导者。

Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

飞利浦2024年的销售额为180亿欧元，约有67,200名员工，在超过100个国家开展销售和服务。有关飞利浦的新闻可在 www.philips.com/newscenter 查阅。